Current efforts for tracking and treating macular disease have focused on the retina, for instance, quantification of drusen distributions, photodynamic therapy (Wormald, Evans, Smeeth, & Henshaw,
2003), and even retinal prostheses for degenerations of the entire retina (Brindlay & Lewin,
1969; Humayun et al.,
2003; Zrenner,
2002). Color photographic images are commonly used for the diagnosis, treatment, and staging of AMD and other macular diseases. Early lesions imaged by fundus photography are the subretinal deposits known as drusen and abnormalities of the retinal pigment epithelium (RPE; Bressler, Bressler, Seddon, Gragoudas, & Jacobson,
1998; Bressler, Maguire, Bressler, & Fine,
1990; Smiddy & Fine,
1984). The late lesions, usually accompanied by severe vision loss, are geographic atrophy (GA) and choroidal neovascularization (CNV; Bressler, Bressler, & Fine,
1988; Sunness, Bressler, Tian, Alexander, & Applegate,
1999; Sunness, Gonzalez-Baron, Bressler, Hawkins, & Applegate,
1999). Besides photography, the eye permits other optical imaging technologies using the scanning laser ophthalmoscope (SLO; Kirkpatrick, Spencer, Manivannan, Sharp, & Forrester,
1995). The SLO can image fundus autofluorescence, the source of which is the lipofuscin in the RPE, and is an important marker in retinal degenerations (Delori, Fleckner, Goger, Weiter, & Dorey,
2000; Smith et al.,
2006; von Rückmann, Fitzke, & Bird,
1997). The SLO can also acquire infrared reflectance scans (Beausencourt, Remky, Elsner, Hartnett, & Trempe,
2000; Elsner, Burns, Weiter, & Delori,
1996), which can reveal other RPE defects, such as drusen and edema. Because tissue sampling of living retinas is quite hazardous, the information in these images is of paramount importance for clinical assessment.